Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine: 50 Years of Modulating the Mind
Linda Li, Phillip E. Vlisides
Frontiers in Human Neuroscience (2016) Vol. 10
Open Access | Times Cited: 319

Showing 1-25 of 319 citing articles:

Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial
Michael S. Avidan, Hannah Maybrier, Arbi Ben Abdallah, et al.
The Lancet (2017) Vol. 390, Iss. 10091, pp. 267-275
Open Access | Times Cited: 419
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji, Gustavo Vázquez, Carlos A. Zarate
Journal of Affective Disorders (2020) Vol. 278, pp. 542-555
Open Access | Times Cited: 302
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 287
New psychoactive substances: a review and updates
Abu Shafi, Alex J. Berry, Harry Sumnall, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 248
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Patricio Molero, Josep Antoni Ramos‐Quiroga, Rocio Martín‐Santos, et al.
CNS Drugs (2018) Vol. 32, Iss. 5, pp. 411-420
Closed Access | Times Cited: 224
Designer drugs: mechanism of action and adverse effects
Dino Luethi, Matthias E. Liechti
Archives of Toxicology (2020) Vol. 94, Iss. 4, pp. 1085-1133
Open Access | Times Cited: 214
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 166
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
Lijia Chang, Kai Zhang, Yaoyu Pu, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 181, pp. 53-59
Closed Access | Times Cited: 151
A historical review of antidepressant effects of ketamine and its enantiomers
Wei Yan, Lijia Chang, Kenji Hashimoto
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172870-172870
Open Access | Times Cited: 142
Microglia enable mature perineuronal nets disassembly upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain
Alessandro Venturino, Rouven Schulz, Hector De Jesús‐Cortés, et al.
Cell Reports (2021) Vol. 36, Iss. 1, pp. 109313-109313
Open Access | Times Cited: 111
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jan Spijker, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 11, pp. 907-921
Open Access | Times Cited: 100
Ketamine treatment for depression: a review
Mani Yavi, Holim Lee, Ioline D. Henter, et al.
Discover Mental Health (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 89
IUPHAR review: Navigating the role of preclinical models in pain research
Seyed Asaad Karimi, Fatama Tuz Zahra, Loren J. Martin
Pharmacological Research (2024) Vol. 200, pp. 107073-107073
Open Access | Times Cited: 20
Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?
Marjorie R. Levinstein, Reece C. Budinich, Jordi Bonaventura, et al.
American Journal of Psychiatry (2025)
Closed Access | Times Cited: 2
Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration
Jennifer W. Evans, Joanna Szczepanik, Nancy E. Brutsché, et al.
Biological Psychiatry (2018) Vol. 84, Iss. 8, pp. 582-590
Open Access | Times Cited: 142
NMDAR Hypofunction Animal Models of Schizophrenia
Gloria Lee, Yi Zhou
Frontiers in Molecular Neuroscience (2019) Vol. 12
Open Access | Times Cited: 128
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Kai Zhang, Kenji Hashimoto
Expert Review of Neurotherapeutics (2018) Vol. 19, Iss. 1, pp. 83-92
Closed Access | Times Cited: 123
Bottom-Up and Top-Down Mechanisms of General Anesthetics Modulate Different Dimensions of Consciousness
George A. Mashour, Anthony G. Hudetz
Frontiers in Neural Circuits (2017) Vol. 11
Open Access | Times Cited: 120
Esketamine for treatment resistant depression
Jennifer Swainson, Rejish K. Thomas, Shaina Archer, et al.
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 10, pp. 899-911
Closed Access | Times Cited: 113
S(+)-ketamine
Helmut Trimmel, Raimund Helbok, Thomas Staudinger, et al.
Wiener klinische Wochenschrift (2018) Vol. 130, Iss. 9-10, pp. 356-366
Open Access | Times Cited: 101
Subanaesthetic ketamine and altered states of consciousness in humans
Phillip E. Vlisides, Tarik Bel‐Bahar, Amanda Nelson, et al.
British Journal of Anaesthesia (2018) Vol. 121, Iss. 1, pp. 249-259
Open Access | Times Cited: 86
Inflammatory signaling mechanisms in bipolar disorder
Gregory Jones, Courtney M. Vecera, Omar F. Pinjari, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 85
The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases
Lauren M. Behlke, Eric J. Lenze, Robert M. Carney
CNS Drugs (2020) Vol. 34, Iss. 11, pp. 1133-1147
Open Access | Times Cited: 80
Novel drug developmental strategies for treatment‐resistant depression
Éva Borbély, Mária Simon, Eberhard Fuchs, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 6, pp. 1146-1186
Open Access | Times Cited: 71
Ketamine treatment for refractory anxiety: A systematic review
Jamie L. Tully, Amelia D. Dahlén, Connor J. Haggarty, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 10, pp. 4412-4426
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top